Is RVMD or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Revolution Medicines N/A -83.22% -59.06% Nuvalent N/A -40.11% -35.43%

Does the media favor RVMD or NUVL?

In the previous week, Revolution Medicines had 10 more articles in the media than Nuvalent. MarketBeat recorded 18 mentions for Revolution Medicines and 8 mentions for Nuvalent. Revolution Medicines' average media sentiment score of 0.36 beat Nuvalent's score of 0.03 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ONC or NUVL?

In the previous week, BeOne Medicines had 2 more articles in the media than Nuvalent. MarketBeat recorded 10 mentions for BeOne Medicines and 8 mentions for Nuvalent. BeOne Medicines' average media sentiment score of 0.92 beat Nuvalent's score of 0.03 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is BNTX or NUVL more profitable?

Nuvalent has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Nuvalent N/A -40.11% -35.43%

Does the media favor BNTX or NUVL?

In the previous week, Nuvalent had 3 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Nuvalent and 5 mentions for BioNTech. BioNTech's average media sentiment score of 0.54 beat Nuvalent's score of 0.03 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, NUVL or INSM?

Nuvalent has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Insmed $606.42M 33.68 -$1.28B -$5.75 N/A

Is NUVL or INSM more profitable?

Nuvalent has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Nuvalent's return on equity of -40.11% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Insmed -144.44% -130.11% -51.57%

Does the media prefer NUVL or INSM?

In the previous week, Insmed had 13 more articles in the media than Nuvalent. MarketBeat recorded 21 mentions for Insmed and 8 mentions for Nuvalent. Insmed's average media sentiment score of 0.84 beat Nuvalent's score of 0.03 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Insmed 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is NUVL or ROIV more profitable?

Nuvalent has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media refer more to NUVL or ROIV?

In the previous week, Roivant Sciences had 3 more articles in the media than Nuvalent. MarketBeat recorded 11 mentions for Roivant Sciences and 8 mentions for Nuvalent. Roivant Sciences' average media sentiment score of 1.17 beat Nuvalent's score of 0.03 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Roivant Sciences 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nuvalent (NUVL) Competitors

$90.95 -3.07 (-3.27%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$90.93 -0.02 (-0.02%)

As of 06/5/2026 06:50 PM Eastern

Compare

NUVL vs. RVMD, ONC, BNTX, INSM, and ROIV

Should you buy Nuvalent stock or one of its competitors? MarketBeat compares Nuvalent with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvalent include Revolution Medicines (RVMD), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Nuvalent compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Nuvalent's return on equity of -40.11% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Nuvalent	N/A	-40.11%	-35.43%

In the previous week, Revolution Medicines had 10 more articles in the media than Nuvalent. MarketBeat recorded 18 mentions for Revolution Medicines and 8 mentions for Nuvalent. Revolution Medicines' average media sentiment score of 0.36 beat Nuvalent's score of 0.03 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Nuvalent has lower revenue, but higher earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,739.75	-$1.13B	-$7.07	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Revolution Medicines presently has a consensus price target of $123.72, suggesting a potential downside of 17.09%. Nuvalent has a consensus price target of $141.24, suggesting a potential upside of 55.29%. Given Nuvalent's higher possible upside, analysts clearly believe Nuvalent is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Summary

Revolution Medicines beats Nuvalent on 8 of the 15 factors compared between the two stocks.

How does Nuvalent compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

BeOne Medicines presently has a consensus price target of $390.00, indicating a potential upside of 44.39%. Nuvalent has a consensus price target of $141.24, indicating a potential upside of 55.29%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts clearly believe Nuvalent is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94

BeOne Medicines has a net margin of 8.94% compared to Nuvalent's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Nuvalent	N/A	-40.11%	-35.43%

In the previous week, BeOne Medicines had 2 more articles in the media than Nuvalent. MarketBeat recorded 10 mentions for BeOne Medicines and 8 mentions for Nuvalent. BeOne Medicines' average media sentiment score of 0.92 beat Nuvalent's score of 0.03 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 5.0% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BeOne Medicines has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.55	$286.93M	$4.47	60.43
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Summary

BeOne Medicines beats Nuvalent on 11 of the 16 factors compared between the two stocks.

How does Nuvalent compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

BioNTech has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Nuvalent has lower revenue, but higher earnings than BioNTech. Nuvalent is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.86	-$1.29B	-$5.88	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuvalent has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Nuvalent	N/A	-40.11%	-35.43%

In the previous week, Nuvalent had 3 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Nuvalent and 5 mentions for BioNTech. BioNTech's average media sentiment score of 0.54 beat Nuvalent's score of 0.03 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

BioNTech presently has a consensus target price of $129.56, indicating a potential upside of 47.10%. Nuvalent has a consensus target price of $141.24, indicating a potential upside of 55.29%. Given Nuvalent's stronger consensus rating and higher probable upside, analysts plainly believe Nuvalent is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94

Summary

BioNTech beats Nuvalent on 8 of the 15 factors compared between the two stocks.

How does Nuvalent compare to Insmed?

Nuvalent (NASDAQ:NUVL) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Nuvalent presently has a consensus price target of $141.24, indicating a potential upside of 55.29%. Insmed has a consensus price target of $210.50, indicating a potential upside of 123.41%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Nuvalent has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Nuvalent's return on equity of -40.11% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Insmed	-144.44%	-130.11%	-51.57%

In the previous week, Insmed had 13 more articles in the media than Nuvalent. MarketBeat recorded 21 mentions for Insmed and 8 mentions for Nuvalent. Insmed's average media sentiment score of 0.84 beat Nuvalent's score of 0.03 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Nuvalent has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Insmed	$606.42M	33.68	-$1.28B	-$5.75	N/A

97.3% of Nuvalent shares are held by institutional investors. 5.0% of Nuvalent shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Nuvalent beats Insmed on 8 of the 15 factors compared between the two stocks.

How does Nuvalent compare to Roivant Sciences?

Nuvalent (NASDAQ:NUVL) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Nuvalent has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

In the previous week, Roivant Sciences had 3 more articles in the media than Nuvalent. MarketBeat recorded 11 mentions for Roivant Sciences and 8 mentions for Nuvalent. Roivant Sciences' average media sentiment score of 1.17 beat Nuvalent's score of 0.03 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Roivant Sciences	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has higher revenue and earnings than Nuvalent. Roivant Sciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Roivant Sciences	$8.26M	2,488.71	-$299.77M	-$0.60	N/A

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 5.0% of Nuvalent shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nuvalent presently has a consensus target price of $141.24, suggesting a potential upside of 55.29%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 17.53%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts plainly believe Nuvalent is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Nuvalent has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Summary

Nuvalent and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Nuvalent News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVL vs. The Competition

Export

Metric	Nuvalent	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.18B	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	-15.01	10.33	20.31	21.86
Price / Sales	N/A	300.34	516.18	112.47
Price / Cash	N/A	51.45	26.99	37.22
Price / Book	5.70	7.97	10.24	6.66
Net Income	-$425.38M	$23.89M	$3.57B	$337.55M
7 Day Performance	-17.61%	-6.96%	-1.28%	-2.52%
1 Month Performance	-11.18%	-2.80%	1.38%	-0.03%
1 Year Performance	16.57%	36.80%	23.93%	25.34%

Nuvalent Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVL Nuvalent	3.4627 of 5 stars	$90.95 -3.3%	$141.24 +55.3%	+16.6%	$7.18B	N/A	N/A	40	Analyst Forecast Insider Trade
RVMD Revolution Medicines	2.105 of 5 stars	$163.68 +3.9%	$122.78 -25.0%	+263.2%	$33.48B	N/A	N/A	250	News Coverage Analyst Forecast Analyst Revision High Trading Volume
ONC BeOne Medicines	4.637 of 5 stars	$279.68 -2.9%	$389.15 +39.1%	+5.6%	$31.59B	$5.34B	62.57	12,000	Analyst Forecast
BNTX BioNTech	3.8842 of 5 stars	$91.70 -4.4%	$129.56 +41.3%	-18.8%	$23.19B	$2.81B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7325 of 5 stars	$106.03 -0.8%	$210.95 +99.0%	+28.0%	$23.17B	$606.42M	N/A	1,664	News Coverage Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUVL) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvalent (NUVL) Competitors

NUVL vs. RVMD, ONC, BNTX, INSM, and ROIV

How does Nuvalent compare to Revolution Medicines?

Summary

How does Nuvalent compare to BeOne Medicines?

Summary

How does Nuvalent compare to BioNTech?

Summary

How does Nuvalent compare to Insmed?

Summary

How does Nuvalent compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVL vs. The Competition

Nuvalent Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvalent (NUVL) Competitors

NUVL vs. RVMD, ONC, BNTX, INSM, and ROIV

How does Nuvalent compare to Revolution Medicines?

Is RVMD or NUVL more profitable?

Does the media favor RVMD or NUVL?

Which has better valuation & earnings, RVMD or NUVL?

Do analysts prefer RVMD or NUVL?

Do insiders and institutionals hold more shares of RVMD or NUVL?

Which has more volatility and risk, RVMD or NUVL?

Summary

How does Nuvalent compare to BeOne Medicines?

Do analysts prefer ONC or NUVL?

Is ONC or NUVL more profitable?

Does the media prefer ONC or NUVL?

Do insiders & institutionals have more ownership in ONC or NUVL?

Which has stronger earnings and valuation, ONC or NUVL?

Which has more volatility & risk, ONC or NUVL?

Summary

How does Nuvalent compare to BioNTech?

Which has more risk & volatility, BNTX or NUVL?

Which has higher valuation & earnings, BNTX or NUVL?

Do insiders and institutionals have more ownership in BNTX or NUVL?

Is BNTX or NUVL more profitable?

Does the media favor BNTX or NUVL?

Do analysts recommend BNTX or NUVL?

Summary

How does Nuvalent compare to Insmed?

Do analysts recommend NUVL or INSM?

Is NUVL or INSM more profitable?

Does the media prefer NUVL or INSM?

Which has more risk and volatility, NUVL or INSM?

Which has higher earnings and valuation, NUVL or INSM?

Do insiders & institutionals have more ownership in NUVL or INSM?

Summary

How does Nuvalent compare to Roivant Sciences?

Is NUVL or ROIV more profitable?

Does the media refer more to NUVL or ROIV?

Which has stronger earnings & valuation, NUVL or ROIV?

Do institutionals and insiders have more ownership in NUVL or ROIV?

Do analysts recommend NUVL or ROIV?

Which has more volatility and risk, NUVL or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVL vs. The Competition

Nuvalent Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools